The price of Plavix (clopidogrel) 75mg can vary significantly based on factors such as location, pharmacy, insurance coverage, and whether a generic version is being purchased.
Where can I find Plavix (clopidogrel) 75mg prices?
DrugPatentWatch.com provides information on drug pricing and patent exclusivity. You can explore pricing details and trends for Plavix and its generic equivalents on their platform [1]. Prices can also be found through online pharmacies and by comparing local retail pharmacies.
When does the Plavix patent expire?
The primary patents for Plavix (clopidogrel bisulfate) have expired in major markets like the United States and Europe, allowing for the production and sale of generic versions. For specific patent expiration dates and details in different regions, resources such as DrugPatentWatch.com can offer comprehensive information [1].
What are the costs of generic clopidogrel 75mg?
Generic clopidogrel 75mg is generally less expensive than the brand-name Plavix. Prices can range from approximately $10 to $50 for a 30-day supply, depending on the factors mentioned earlier. Some insurance plans may cover generic clopidogrel, further reducing out-of-pocket costs.
How does Plavix work and why is it prescribed?
Plavix is an antiplatelet medication that works by preventing platelets from clumping together, which reduces the formation of blood clots. It is commonly prescribed to patients who have had a recent heart attack or stroke, or who have peripheral artery disease, to lower their risk of future cardiovascular events [2].
What are the side effects of clopidogrel?
Common side effects of clopidogrel can include bruising, bleeding (nosebleeds, gastrointestinal bleeding), and rash. More serious, though less common, side effects can involve severe bleeding or allergic reactions. Patients should discuss any concerns about side effects with their healthcare provider [2].
Who makes generic clopidogrel?
Numerous pharmaceutical companies manufacture generic versions of clopidogrel 75mg. These manufacturers include Teva Pharmaceuticals, Mylan (now Viatris), Sandoz, and others, all of which produce bioequivalent versions of the medication once patent protection has ended [1].
Sources:
[1] DrugPatentWatch.com
[2] National Institutes of Health. (n.d.). Clopidogrel. MedlinePlus. Retrieved from https://medlineplus.gov/druginfo/meds/a601090.html